No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin

Theravance is the latest company to be caught in a web created by FDA's ongoing examination of its approach to evaluating new antibiotics. In a move widely anticipated by Wall Street analysts and Theravance alike, FDA sent a "complete response" letter Nov. 27 asking the drug maker for additional data and analyses for its telavancin (Vibativ) application for nosocomial pneumonia

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet